Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.

Toxicology and applied pharmacology - 15 Oct 2022

Mullaguri Sai Charitha, Akula Sravani, Ashireddygari Vigneshwar Reddy, Sahoo Partha Sarathi, Burra V L S Prasad, Silveri Ravalika, Mupparapu Vyshnavika, Korikani Meghana, Amanchi Nageswara Rao, Subramanian Janakiraman, Kancha Rama Krishna

Abstract excerpt

Current experimental and clinical data are inadequate to conclusively predict the oncogenicity of uncommon BRAF mutants and their sensitivity towards kinase inhibitors. Therefore, the present study aims at estimating sensitivity profiles of uncommon lung cancer specific BRAF mutations towards clinically approved as well as experimental therapeutics based on computationally derived direct binding energies. Based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sorafenib

Source

Identifiers

PMID: 36049549
DOI: 10.1016/j.taap.2022.116213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.PMID 36049549Read ↗

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.Semantic proximity Read ↗

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanySemantic proximity Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer.Semantic proximity Read ↗

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutationsSemantic proximity Read ↗

A BRAF new world.Semantic proximity Read ↗

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Semantic proximity Read ↗

Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.Semantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

<i>In Vitro</i> Validation of Computationally Predicted Oncogenic Driver Mutations in EGFR Tyrosine Kinase DomainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.